Please use this identifier to cite or link to this item:
|Title:||Immunocompromised patients with metastatic cutaneous nodal squamous cell carcinoma of the head and neck: Poor outcome unrelated to the index lesion||Authors:||Lam, Johnson K S ;Sundaresan, P.;Veness, M.J.;Gebski, V.||Affliation:||Central Coast Local Health District
|Issue Date:||May-2018||Source:||40(5):985-992||Journal title:||Head & neck||Department:||Radiation Oncology||Abstract:||BACKGROUND: Immunocompromised patients with metastatic cutaneous nodal head and neck squamous cell carcinoma (HNSCC) have worse outcomes compared to the immunocompetent. The purpose of this study was to investigate the characteristics of the primary cutaneous squamous cell carcinoma (SCC), nodal pathology, and outcome between these 2 groups. METHODS: Analysis of a prospective database was performed. A 2:1 pooled analysis selected 46 immunocompetent patients matched with 23 immunocompromised patients. Overall survival (OS) and relapse-free survival (RFS) were calculated using the Kaplan-Meier method. RESULTS: No significant difference was found in the primary tumor characteristics between the 2 groups. In the immunocompromised group, RFS (hazard ratio [HR] 2.70; P = .01) and OS (HR 2.32; P = .04) were significantly worse. Extracapsular spread was present in 100% of the immunocompromised patients. CONCLUSION: No significant difference was identified in the primary cutaneous SCC between the immunocompetent and immunocompromised patients. Immunosuppression predicted worse outcome.||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1454||DOI:||10.1002/hed.25069||Pubmed:||https://www.ncbi.nlm.nih.gov/pubmed/29360262||ISSN:||1043-3074||Publicaton type:||Journal Article||Keywords:||Cancer|
|Appears in Collections:||Oncology / Cancer|
Show full item record
checked on Jun 4, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.